Facing tens of thousands of lawsuits over cancer risks on the popular heartburn drug Zantac, GSK has argued there's "no consistent or reliable evidence" that the medi...

Biogen will soon have a new board leader, potentially giving new CEO Chris Viehbacher more freedom to make bold moves to salvage the big biotech from declining revenu...

Teva's new CEO Richard Francis has his work cut out as the company seeks to recover from a revenue slide. Thanks to declines for several of its offerings, Teva...

As Vertex Therapeutics nears completion of a historic FDA submission, the rare disease specialist has depicted a rosy launch picture for what could become the first C...

You may have been enthralled by the Adele/Harry Styles drama, but Big Pharma also had a big night at the 65th Annual Grammy Awards this week. While the Super B...

The calls for a new Bayer CEO have been answered. Bill Anderson, most recently Roche’s pharmaceutical chief, will become Bayer’s new group CEO starting in June...

If there were ever a place to talk about showing some skin, it’s the Grammy Awards. Amid all the sparkle and star power of the event, Bristol Myers Squibb launched it...

Working to grow the reach of its sickle cell disease medicine Adakveo, Novartis has more than just Pfizer's Oxbryta to worry about. After a phase 3 trial miss,...

Italian drugmaker Menarini has succeeded where European Big Pharmas have failed, pushing the first oral selective estrogen receptor degrader (SERD) to treat breast ca...

Hundreds of manufacturing jobs are in limbo as Sanofi weighs operations at a pair of vaccine plants overseas, marking the latest in an onslaught of job cuts across th...